Medical Center in Montreal Treats First Breast Cancer Patient with Clinical Trial Drug

Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) said Wednesday that VM Medical Center in Montreal has treated its first patient of its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study. The VM Medical Center is the largest private breast center in Canada.
As quoted in the press release:

John R. Keyserlingk, MD, MSC, FRCS©, FACS, Surgical Oncologist and Director of the VM Breast and Oncology Center stated, ” I and my multi-disciplinary team involved with breast cancer management are very pleased to have treated our first patient of this Phase III pivotal study for the treatment of Locally Advanced Breast Cancer. Combining pre-operative microwave thermotherapy to the involved breast, alongside our best chemotherapy, has the potential to significantly reduce the tumour burden beyond what can be provided by chemotherapy alone. When all, or nearly all, the tumour cells have been eliminated by the time the patient undergoes surgery, she then benefits from both best survival prognosis, and a reduced need for total mastectomy, the latter usually required for patients with large breast tumors. Upon successful completion of the study, and if approved, this technology will offer our patients, and many other breast cancer patients, additional and greatly needed treatment options, including potentially reducing the size of the surgical interventions. ” 

Read the full press release by Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF)